Drug intelligence / Profile preview

aflapin + uc-ii collagen

Development stage
Unknown
Lead developer
Vivital Pharma
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral
01

Overview

**Aflapin + UC-II collagen** is a fixed-dose combination product containing Aflapin (a proprietary Boswellia serrata gum resin extract standardized to high AKBA content) and undenatured type II collagen (UC-II). It is primarily used as a nutritional supplement to reduce symptoms of osteoarthritis and improve joint flexibility and function. The mechanism of action involves: - **Aflapin:** Inhibits inflammatory pathways by selectively blocking 5-lipoxygenase (5-LOX), reducing pro-inflammatory mediators such as leukotrienes, TNF-α, IL-1β, IL-2, and IL-17, and prevents cartilage degradation by inhibiting MMP-3 and MMP-13. - **UC-II collagen:** Induces oral tolerance, activating T regulatory (Treg) cells, which increase production of anti-inflammatory cytokines like IL-4, IL-10, and TGF-β, stimulating chondrocytes and promoting cartilage repair and regeneration. Clinical studies suggest this combination can slow osteoarthritis progression and serve as a safer long-term alternative to NSAIDs. It is taken orally, often as a once-daily capsule, and is generally well tolerated, with possible mild gastrointestinal side effects. It is not indicated for use during pregnancy or lactation due to insufficient safety data[1][3][5][7].

Brand names
Vylex
Other names
aflapin + native collagen type iiaflapin + undenatured type ii collagenaflapin + uc-ii
02

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)COL2 (Type II Collagen)

Beyond the preview

Go deeper on aflapin + uc-ii collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aflapin + uc-ii collagen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call